SWOT Analysis for Jubilant Pharmova Ltd. - Strengths

Add SWOT widget to your site/app

MACD Crossover Above Signal Line

Price crossing above SMA20 today, and greater than SMA5

Companies with current TTM PE Ratio less than 3 Year, 5 Year and 10 Year PE

Strong Performer, Under Radar Stocks (DVM)

Consistent Highest Return Stocks over Five Years - Nifty500

Relative Outperformance versus Industry over 1 Month

Relative Outperformance versus Industry over 1 Year

Companies with high TTM EPS Growth

Annual Profit Growth higher than Sector Profit Growth

PEG lower than Industry PEG

Relative Outperformance versus Industry over 1 Week

Relative Outperformance versus Industry over 1 Month

Companies with Net Profit TTM 5X that of Net Profit in Previous Year

Growth in Quarterly Net Profit with increasing Profit Margin (YoY)

Increasing Revenue every quarter for the past 2 quarters

Book Value per share Improving for last 2 years

Companies with Zero Promoter Pledge

High Volume, High Gain

MACD crossed above signal line previous end of day

Biggest Price Gainers from Open

Top Gainers

High Volume, High Gain

Volume Shockers

Stocks Outperforming their Industry Price Change in the Quarter

Companies with growing costs YoY for long term projects

Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score

Declining profits every quarter for the past 2 quarters

Declining Net Cash Flow : Companies not able to generate net cash

Mutual Funds Increased Shareholding in Past Month

FII / FPI or Institutions increasing their shareholding

MFs increased their shareholding last quarter

Mutual Funds Increased Shareholding over the Past Two Months

Mf buying for 2 months

US FDA Warning Letter

Average Affordability - Stocks with Medium Trendlyne Valuation Score versus Benchmarks

Decline in Net Profit with falling Profit Margin (QoQ)